BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-10 01:30 |
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosin…
|
English | 211.0 KB | ||
| 2024-05-24 12:55 |
Leqembi[®] godkänt för behandling av Alzheimers sjukdom i Sydkorea
|
Swedish | 218.0 KB | ||
| 2024-05-24 12:55 |
Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
|
English | 193.0 KB | ||
| 2024-05-22 18:00 |
Bulletin from the Annual General Meeting in BioArctic AB (publ)
|
English | 153.3 KB | ||
| 2024-05-22 18:00 |
Kommuniké från årsstämma i BioArctic AB (publ)
|
Swedish | 149.4 KB | ||
| 2024-05-17 08:00 | Swedish | 1.5 MB | |||
| 2024-05-17 08:00 | English | 1.2 MB | |||
| 2024-05-15 05:45 |
Eisai förväntar sig att försäljningen av Leqembi® kommer uppgå till 56,5 miljar…
|
Swedish | 230.6 KB | ||
| 2024-05-15 05:45 |
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 …
|
English | 196.3 KB | ||
| 2024-05-15 01:30 |
Eisai påbörjar stegvis ansökan till FDA för subkutan underhållsbehandling med L…
|
Swedish | 228.0 KB | ||
| 2024-04-24 12:45 |
Försäljningen av Leqembi® uppgick till 2,83 miljarder yen under det första kvar…
|
Swedish | 229.1 KB | ||
| 2024-04-24 12:45 |
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
|
English | 194.8 KB | ||
| 2024-04-20 09:40 |
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
|
English | 147.0 KB | ||
| 2024-04-20 09:40 |
BioArctic och Eisai ingår forskningsutvärderingsavtal avseende BAN2802
|
Swedish | 171.1 KB | ||
| 2024-04-19 08:00 |
Kallelse årsstämma 2024 BioArctic AB (publ)
|
Swedish | 203.8 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
